Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 13 | 2022 | 85 | 3.830 |
Why?
|
| Action Potentials | 12 | 2022 | 79 | 2.890 |
Why?
|
| Calcium | 7 | 2022 | 354 | 2.440 |
Why?
|
| Calcium Signaling | 7 | 2022 | 110 | 1.850 |
Why?
|
| Heart Atria | 7 | 2023 | 22 | 1.730 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2023 | 12 | 1.570 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 97 | 1.340 |
Why?
|
| Calcium Channels, L-Type | 5 | 2019 | 50 | 1.290 |
Why?
|
| Rabbits | 9 | 2023 | 165 | 1.240 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 57 | 1.160 |
Why?
|
| Animals | 16 | 2023 | 3293 | 1.070 |
Why?
|
| Chloride Channels | 2 | 2016 | 7 | 0.980 |
Why?
|
| Peptide Hormones | 1 | 2023 | 3 | 0.840 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2023 | 17 | 0.840 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 5 | 0.780 |
Why?
|
| Heart Failure | 1 | 2023 | 141 | 0.740 |
Why?
|
| Myocardial Contraction | 3 | 2017 | 36 | 0.700 |
Why?
|
| Membrane Potentials | 3 | 2022 | 166 | 0.700 |
Why?
|
| Sarcoplasmic Reticulum | 5 | 2022 | 157 | 0.580 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2017 | 1 | 0.540 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 44 | 0.520 |
Why?
|
| Heart | 1 | 2017 | 59 | 0.510 |
Why?
|
| Calcium Channels | 1 | 2017 | 106 | 0.500 |
Why?
|
| Chloride Channel Agonists | 1 | 2016 | 1 | 0.500 |
Why?
|
| Excitation Contraction Coupling | 1 | 2014 | 9 | 0.450 |
Why?
|
| Patch-Clamp Techniques | 4 | 2017 | 97 | 0.430 |
Why?
|
| Electrocardiography | 1 | 2014 | 92 | 0.430 |
Why?
|
| Quinolinium Compounds | 1 | 2012 | 1 | 0.380 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2012 | 1 | 0.380 |
Why?
|
| 2-Naphthylamine | 1 | 2012 | 3 | 0.380 |
Why?
|
| Body Surface Potential Mapping | 1 | 2012 | 2 | 0.380 |
Why?
|
| Pyridinium Compounds | 1 | 2012 | 5 | 0.380 |
Why?
|
| Heart Conduction System | 1 | 2012 | 6 | 0.380 |
Why?
|
| Gap Junctions | 3 | 2008 | 11 | 0.370 |
Why?
|
| Heart Ventricles | 3 | 2017 | 82 | 0.350 |
Why?
|
| Sodium-Calcium Exchanger | 2 | 2022 | 9 | 0.350 |
Why?
|
| Cyclic AMP | 1 | 2008 | 31 | 0.280 |
Why?
|
| Ion Channel Gating | 1 | 2008 | 176 | 0.250 |
Why?
|
| Male | 7 | 2020 | 12438 | 0.220 |
Why?
|
| Potassium Channels | 2 | 2018 | 36 | 0.220 |
Why?
|
| Angiotensin II | 1 | 2023 | 3 | 0.210 |
Why?
|
| Calmodulin | 1 | 2023 | 7 | 0.210 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2023 | 20 | 0.210 |
Why?
|
| Connexins | 3 | 2008 | 3 | 0.210 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2022 | 1 | 0.200 |
Why?
|
| Apamin | 1 | 2022 | 3 | 0.200 |
Why?
|
| Sodium | 1 | 2022 | 56 | 0.180 |
Why?
|
| Myocardium | 1 | 2022 | 100 | 0.180 |
Why?
|
| Maf Transcription Factors, Large | 1 | 2020 | 2 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 13 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2020 | 22 | 0.160 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 11 | 0.160 |
Why?
|
| Heart Rate | 1 | 2020 | 104 | 0.160 |
Why?
|
| Cells, Cultured | 3 | 2019 | 465 | 0.160 |
Why?
|
| Uncoupling Agents | 1 | 2019 | 4 | 0.150 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2019 | 5 | 0.150 |
Why?
|
| beta Catenin | 1 | 2020 | 57 | 0.150 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2017 | 2 | 0.140 |
Why?
|
| Rana esculenta | 1 | 2017 | 2 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2017 | 13 | 0.140 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 21 | 0.140 |
Why?
|
| Muscle Cells | 1 | 2017 | 12 | 0.140 |
Why?
|
| Isoproterenol | 1 | 2017 | 13 | 0.140 |
Why?
|
| Mitochondria | 1 | 2017 | 55 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2017 | 5 | 0.130 |
Why?
|
| Kinetics | 1 | 2017 | 176 | 0.130 |
Why?
|
| Models, Biological | 1 | 2017 | 302 | 0.120 |
Why?
|
| Humans | 8 | 2020 | 22913 | 0.110 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2014 | 13 | 0.110 |
Why?
|
| Ion Transport | 1 | 2014 | 28 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2014 | 34 | 0.110 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2014 | 134 | 0.100 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 34 | 0.090 |
Why?
|
| Swine | 1 | 2012 | 68 | 0.090 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2019 | 14 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 7 | 0.090 |
Why?
|
| Connexin 26 | 2 | 2008 | 2 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 443 | 0.090 |
Why?
|
| Light | 1 | 2011 | 55 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 593 | 0.080 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2008 | 4 | 0.070 |
Why?
|
| Connexin 43 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2008 | 9 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2008 | 22 | 0.070 |
Why?
|
| Diffusion | 1 | 2008 | 24 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cell Communication | 1 | 2008 | 21 | 0.070 |
Why?
|
| Electric Conductivity | 1 | 2008 | 68 | 0.070 |
Why?
|
| Cataract | 1 | 2008 | 19 | 0.070 |
Why?
|
| Point Mutation | 1 | 2008 | 25 | 0.070 |
Why?
|
| Permeability | 1 | 2008 | 94 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2008 | 50 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 239 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2019 | 54 | 0.060 |
Why?
|
| Diuretics, Osmotic | 1 | 2005 | 3 | 0.060 |
Why?
|
| Mannitol | 1 | 2005 | 11 | 0.060 |
Why?
|
| Albuterol | 1 | 2005 | 14 | 0.060 |
Why?
|
| Rats | 2 | 2019 | 627 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 1263 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 14 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 28 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 139 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 4 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 3 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2020 | 19 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 39 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 52 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2020 | 48 | 0.040 |
Why?
|
| Insulin | 1 | 2020 | 77 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 173 | 0.040 |
Why?
|
| Proton Ionophores | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 161 | 0.040 |
Why?
|
| Gene Expression | 1 | 2020 | 176 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 173 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2020 | 281 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 260 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2020 | 149 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 370 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2008 | 34 | 0.030 |
Why?
|
| Electrophysiology | 2 | 2008 | 95 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 117 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 1249 | 0.030 |
Why?
|
| Female | 2 | 2020 | 12935 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 1 | 0.020 |
Why?
|
| Biotin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 7 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2008 | 12 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 17 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 20 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 53 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 67 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 111 | 0.020 |
Why?
|
| Connexin 30 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2007 | 1 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2007 | 2 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 5 | 0.020 |
Why?
|
| Anions | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cations | 1 | 2007 | 15 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 19 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 34 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 232 | 0.020 |
Why?
|
| Osmotic Pressure | 1 | 2005 | 4 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 17 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 314 | 0.010 |
Why?
|
| Adult | 1 | 2005 | 6912 | 0.010 |
Why?
|
| Aged | 1 | 2005 | 7429 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 7895 | 0.010 |
Why?
|